Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

07/31/2020 | 05:56pm EDT
FILE PHOTO: A GSK logo is seen at the GSK research centre in Stevenage

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.

The drugmakers also said they are in advanced discussions to supply up to 300 million doses of the experimental vaccine for the 27-country European Union.

The U.S. award is the biggest yet from 'Operation Warp Speed', the White House initiative aimed at accelerating access to vaccines and treatments to fight COVID-19, the respiratory disease caused by the novel coronavirus.

The deal, announced by the U.S. Department of Health and Human Services and Department of Defense, works out at a cost of around $42 per person inoculated.

That is almost identical to the $40 per patient the U.S. agreed to pay Pfizer Inc and BioNTech SE when it inked a nearly $2 billion deal for 50 million courses of that potential vaccine last week.

The Sanofi-GSK deal is for 100 million doses, at two per person, and gives the U.S. government an option to purchase an additional 500 million doses at an unspecified price. Sanofi and GSK plan to start clinical trials for the vaccine in September.

Sanofi executive Clement Lewin said the companies had not yet agreed with the U.S. on a specific price for the additional doses.

GSK said in a statement that more than half of the total funding will go into further development of the vaccine, including clinical trials, with the remainder used for a manufacturing ramp-up and delivery of doses.

The two companies' inoculation is combination of a vaccine based on Sanofi's flu shots and a complementary technology from GSK called an adjuvant, designed to improve the vaccine's potency.

Sanofi will receive the bulk of the proceeds from the deal.

It marks the second contract for the Franco-British pair's vaccine candidate after they agreed earlier this week to supply 60 million doses to the British government.

Reuters reported last week that Pfizer's deal was expected to set a pricing benchmark for future deals between drugmakers and governments.

Moderna Inc and Pfizer began two 30,000-subject trials of COVID-19 vaccines on Monday that could clear the way for regulatory approval and use by the end of 2020.

(Reporting by Michael Erman and Carl O'Donnell in New York; Additional reporting by Ludwig Burger in Frankfurt and Deena Beasley in Los Angeles; editing by Jan Harvey and Grant McCool)

By Michael Erman and Carl O'Donnell

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 6.44% 226.09 Delayed Quote.160.57%
GLAXOSMITHKLINE PLC -0.59% 1415 Delayed Quote.6.07%
MODERNA, INC. 4.54% 208.24 Delayed Quote.90.67%
PFIZER, INC. 1.57% 39.42 Delayed Quote.5.43%
SANOFI 0.27% 88.22 Real-time Quote.11.79%
02:38pDual-antibody drugs effective against COVID-19 variants in animal study
09:23aWALL STREET STOCK EXCHANGE : A series of Fed official speeches is on the way
09:21aSECTOR UPDATE : Health Care Stocks Edge up Pre-Bell Monday
08:26aStudy confirms GSK-Vir antibody drug reduces hospitalization, death in COVID-..
08:13aVIR BIOTECHNOLOGY  : GSK's Phase 3 Trial of COVID-19 Monoclonal Antibody Meets P..
07:45aASTRAZENECA  : GSK to boost spending power of pharma business post break-up
07:09aGLAXOSMITHKLINE  : GSK and Vir Biotechnology announce continuing progress of the..
07:03aVIR BIOTECHNOLOGY  : GSK, Vir To Test Giving Sotrovimab Intramuscularly For Mild..
06:46aANALYST RECOMMENDATIONS : BT Group, FIGS, Intel, Ocado, Rio Tinto...
06:16aGLAXOSMITHKLINE  : Barclays reiterates its Sell rating
More news
Sales 2021 33 150 M 46 177 M 46 177 M
Net income 2021 3 572 M 4 975 M 4 975 M
Net Debt 2021 21 537 M 30 000 M 30 000 M
P/E ratio 2021 20,3x
Yield 2021 5,59%
Capitalization 70 805 M 98 542 M 98 630 M
EV / Sales 2021 2,79x
EV / Sales 2022 2,61x
Nbr of Employees 94 066
Free-Float 92,3%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 27
Average target price 1 514,83 GBX
Last Close Price 1 423,40 GBX
Spread / Highest target 35,2%
Spread / Average Target 6,42%
Spread / Lowest Target -24,8%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795